Clinical Trial: Xbiotech PT049

Trial Status: Open
Disease Type: Pancreatic
Trial ID Xbiotech PT049
Sponsor ID Xbiotech USA Inc

A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer

Principal Investigator
Keeran R. Sampat, MD
3 Locations


Arlington Office

Fairfax Office

Gainesville Office

Learn More About This Trial

Other Relevant Trials
Trial ID 21235
Sponsor ID Comet

A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

Principal Investigator
Keeran R. Sampat, MD
3 Locations
Trial ID NBF-006
Sponsor ID Nitto BioPharma

A Phase 1/1b Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF-006 in Patients with Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients with KRAS-Mutated Non-Small Cell Lung Cancer.